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Munich, GermanyObjectives This study sought to compare the risk of stent thrombosis among patients treated with
bare-metal stents (BMS), ﬁrst-generation drug-eluting stents (G1-DES), and second-generation
drug-eluting stents (G2-DES) for a period of 3 years.
Background In patients undergoing coronary stenting, there is a scarcity of long-term follow-up data
on cohorts large enough to compare rates of stent thrombosis across the stent generations.
Methods A total of 18,334 patients undergoing successful coronary stent implantation from 1998 to
2011 at 2 centers in Munich, Germany, were included in this study. Patients were stratiﬁed into
3 groups according to treatment with BMS, G1-DES, and G2-DES.
Results The cumulative incidence of deﬁnite stent thrombosis at 3 years was 1.5% with BMS, 2.2%
with G1-DES, and 1.0% with G2-DES. On multivariate analysis, G1-DES compared with BMS showed
a signiﬁcantly higher risk of stent thrombosis (odds ratio [OR]: 2.05; 95% conﬁdence interval [CI]:
1.47 to 2.86; p < 0.001). G2-DES were associated with a similar risk of stent thrombosis compared with
BMS (OR: 0.82; 95% CI: 0.56 to 1.19; p ¼ 0.30). Beyond 1 year, the risk of stent thrombosis was
signiﬁcantly increased with G1-DES compared with BMS (OR: 4.72; 95% CI: 2.01 to 11.1; p < 0.001), but
not with G2-DES compared with BMS (OR: 1.01; 95% CI: 0.32 to 3.25; p ¼ 0.98).
Conclusions In a large cohort of unselected patients undergoing coronary stenting, compared with
BMS, there was a signiﬁcant excess risk of stent thrombosis at 3 years with G1-DES, driven by an
increased risk of stent thrombosis events beyond 1 year. G2-DES were associated with a similar risk of
stent thrombosis compared with BMS. (J Am Coll Cardiol Intv 2013;6:1267–74) ª 2013 by the
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1268Stent thrombosis is a rare but frequently fatal complica-
tion of percutaneous coronary intervention (1,2). First-
generation drug-eluting stents (G1-DES), compared with
bare-metal stents (BMS), markedly reduce the need for
reinterventions (3–6). However, the risk to be borne appears
to be a small but continuous increase in the incidence of
stent thrombosis in the late phase after stent implantation
(7–9). Pathological samples of patients with stent throm-
bosis conﬁrmed that G1-DES lead to delayed arterial
healing, incomplete endothelialization, and persistent ﬁbrin
deposition compared with BMS (10). The use of durable
polymer coatings, the thickness of the stent struts, and the
dose of the antiproliferative drug and its release kinetics have
been implicated as important contributing factors in these
late adverse events (11–13). Against this background,
second-generation DES (G2-DES) were developed that
have improved biocompatibility, durable or biodegradable
polymer coatings, thinner stent struts, and improved anti-
proliferative drug release kinetics. Indeed G2-DES haveAbbreviations
and Acronyms
BMS = bare-metal stent(s)
CI = conﬁdence interval





OR = odds ratio
STEMI = ST-segment
elevation myocardial
infarctionshown favorable safety and efﬁ-
cacy compared with G1-DES
in a number of clinical trials
and registries (14–18). To date,
however, there is a scarcity of
long-term follow-up data on
real-world patients in cohorts
large enough to compare rates of
stent thrombosis with adequate
statistical power across different
generations of stents. The aim of
this study was to compare the
relative risk of stent thrombosis
among 3 different stent genera-
tions, BMS, G1-DES, and G2-DES, from a dataset of 18,334 patients with coronary artery
disease treated with intracoronary stents over a 13-year
period.
Methods
Patient selection and study procedures. We analyzed clin-
ical, angiographic, and procedural data for all consecutive
patients treated with stent implantation for coronary artery
disease between January 1998 and December 2011 in 2
tertiary referral centers in Munich, Germany (Deutsches
Herzzentrum and 1. Medizinische Klinik, Klinikum Rechts
der Isar) provided that written informed consent was
obtained. Patients receiving long-term renal replacement
therapy and those who had undergone previous cardiac
transplantation or with stent thrombosis as an indication for
intervention were excluded. BMS were the sole platforms
approved for use from January 1998 to August 2002.
Thereafter, DES became available. DES were arbitrarily
subclassiﬁed as ﬁrst or second generation. G1-DEScomprised durable polymer (polyethylene-co-vinyl acetate
and poly-N-butyl-methacrylate sirolimus-eluting stents
(Cypher, Cordis, Warren, New Jersey); durable polymer
(Translute) paclitaxel-eluting stents (Taxus, Boston Scien-
tiﬁc, Natick, Massachusetts), durable polymer (phosphor-
ylcholine) zotarolimus-eluting stents (Endeavor, Medtronic
Inc., Santa Rosa, California), and polymer-free sirolimus-
eluting stents (Yukon, Translumina GmbH, Hechingen,
Germany); the majority of G1-DES were Cypher and
Taxus stents. G2-DES were available starting in January
2006 and comprised durable ﬂuoropolymer everolimus-
eluting stents (Xience V, Abbott Vascular, Santa Clara,
California), durable polymer (BioLinx) zotarolimus-eluting
stents (Resolute, Medtronic Inc.), biodegradable polymer
biolimus A9-eluting stents (Nobori, Terumo Corporation,
Tokyo, Japan), biodegradable polymer sirolimus-eluting
stents and polymer-free sirolimus and probucol-eluting
stents (both Yukon; Translumina GmbH); the majority of
2G-DES were Xience and Resolute stents. The assignment
to BMS or DES platforms occurred predominantly in the
setting of randomized trials; typically, the same stent was
implanted in a patient undergoing multilesion interventions.
Antithrombotic and anticoagulant therapies reﬂected the
changing practices during the period of observation. Until
April 1999, in patients undergoing a percutaneous coronary
intervention, we used the ticlopidine therapy regimen,
which comprised a pre-treatment dose of 500 mg given
orally 1 to several hours before the procedure followed by
a 500-mg/day maintenance dose. From May to August
1999, patients received clopidogrel therapy consisting of
pre-treatment with an oral dose of 300 mg given 2 to 4 h
before the intervention, 150 mg/day until discharge, and
a maintenance dose of 75 mg/day. Since September 1999,
we initiated a high loading clopidogrel regimen with an oral
dose of 600 mg of clopidogrel, 150 mg/day until discharge,
and a maintenance dose of 75 mg/day. After the interven-
tion, all patients, irrespective of treatment allocation, were
prescribed 200 mg/day of aspirin indeﬁnitely, whereas
ticlopidine or clopidogrel was prescribed for a period of at
least 1 month after BMS implantation and at least 6 months
after DES implantation. During coronary intervention, all
patients received anticoagulation with either unfractionated
heparin or bivalirudin. Administration of glycoprotein IIb/
IIIa inhibitors and the use of intracoronary imaging was at
the discretion of the operating physician. After the inter-
vention, patients remained in the hospital for at least 48 h.
Blood samples were drawn every 8 h for the ﬁrst 24 h after
randomization and daily afterward for the determination of
cardiac markers (creatine kinase, creatine kinase-myocardial
band, troponin T or I). Daily electrocardiography was also
performed until discharge. All patients were prescribed
standard secondary prevention for coronary artery disease as
directed by the treating physician (e.g., beta-blockers, sta-
tins, angiotensin-converting enzyme inhibitors, and other
Figure 1. Study Flow Chart
Patients treated with coronary stents during the study period. DES ¼ drug-
eluting stent(s).
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1269drugs). All patients were then evaluated at 1, 12, and 36
months by phone or ofﬁce visit.
Data management, endpoints, and deﬁnitions. Relevant data
were collected and entered into a computer database by
specialized personnel of the Clinical Data Management
Center. All events were adjudicated and classiﬁed by an
event adjudication committee blinded to the treatment
groups. Baseline, post-procedural, and follow-up coronary
angiograms were digitally recorded and assessed ofﬂine in
the quantitative angiographic core laboratory (ISAResearch
Center, Munich, Germany) with an automated edge-
detection system (CMS version 7.1, Medis Medical Imaging
Systems, Leiden, the Netherlands) by independent experi-
enced operators unaware of the treatment allocation.
Measurements were performed on cine angiograms recorded
after the intracoronary administration of nitroglycerin using
the same single worst-view projection at all times. The
contrast-ﬁlled nontapered catheter tip was used for calibra-
tion. Quantitative analysis was performed on both the in-
stent and in-segment area (including the stented segment as
well as both 5-mm margins proximal and distal to the stent).
Qualitative morphological lesion characteristics were char-
acterized by standard criteria.
The primary endpoint was the 3-year Academic Research
Consortium deﬁnite stent thrombosis conﬁrmed by angi-
ography or autopsy (19). The secondary endpoint was very
late deﬁnite stent thrombosis occurring beyond 1 year.
Successful stent implantation was achieved if residual
stenosis after intervention was <30% with Thrombolysis In
Myocardial Infarction ﬂow grade 3. Risk factors and
comorbidities in each patient were determined as recorded
by the treating physician. Acute coronary syndrome was
deﬁned as acute myocardial ischemia on the basis of clinical
symptoms, electrocardiography changes, and increase in
cardiac biomarkers and comprised acute ST-segment
elevation myocardial infarction (STEMI), non-STEMI, and
unstable angina.
Statistical analysis. Categorical data are presented as count
and percentage. Continuous data are presented as median
and interquartile range (25th, 75th percentiles) or mean 
SD, as appropriate. Data distribution was tested for
normality using the Kolmogorov-Smirnov test. For patient
level data, the differences among groups were checked for
signiﬁcance using the Student t or Kruskal-Wallis test
(continuous data) or the chi-square test. For lesion-level
data, differences among groups were checked for statistical
signiﬁcance using generalized estimating equations for non-
normally distributed data to address intrapatient correlation
in patients who underwent multilesion interventions (20).
The incidence of stent thrombosis was calculated at lesion
level. For 3-year overall stent thrombosis, cumulative inci-
dence was estimated with the Kaplan-Meier method, and
differences among groups were tested with the log-rank
test. For very late stent thrombosis beyond 1 year, incidencerates were calculated relative to the number of patient-years
under observation (expressed as the number of events/1,000
patient-years). In contrast to crude percentages, incidence
rates take into account differences in the follow-up duration
among stent generations. A multivariate regression analysis
was performed to assess predictors of stent thrombosis. All
clinical, angiographic, and procedural features reporting
a p value <0.05 on univariate analysis were included in the
model. Adjusted odds ratios (ORs) with 95% conﬁdence
intervals (CIs) were used as summary statistics and were
derived from generalized estimating equation models. The
statistical software package R version 2.15.2 (R Foundation
for Statistical Computing, Vienna, Austria) was used for
analyses. The R package gee was used to perform multi-
variate analyses (21).
Results
Overall 3-year incidence of deﬁnite stent thrombosis. The
18,334 patients with 28,739 lesions enrolled in this study
were treated as follows: 7,410 patients (40.4%) received
BMS in 10,708 lesions; 3,831 patients (20.9%) received G1-
DES in 5,872 lesions; and 7,093 patients (38.7%) received
G2-DES in 12,159 lesions (Fig. 1). Baseline clinical char-
acteristics and lesion and procedural characteristics among
BMS, G1-DES, and G2-DES are shown in Online Tables
1 and 2.
At 3 years, deﬁnite stent thrombosis had occurred in 246
patients (1.3%) with 292 lesions. All the stent thromboses
were conﬁrmed by angiography. Baseline clinical charac-
teristics differed signiﬁcantly between those with and
without stent thrombosis at 3 years (Table 1). In addition,





No. of patients 246 18,088
Age, yrs 65.9  12.0 66.9  11.4 0.25
Female 57 (23.2) 4,678 (25.9) 0.39
Body mass index, kg/m2 27.0  4.4 27.2  4.3 0.55
Diabetes mellitus 96 (39.0) 4,664 (25.8) <0.001
Insulin-treated 35 (14.2) 1,466 (8.1) 0.001
Hypertension 132 (53.7) 11,609 (64.2) 0.001
Hyperlipidemia 153 (62.2) 10,986 (60.7) 0.69
Current smoker 67 (27.2) 3,794 (21.0) 0.02
Previous MI 100 (40.7) 4,326 (23.9) <0.001
Previous bypass surgery 28 (11.4) 2,102 (11.6) >0.99
Multivessel disease 210 (85.4) 13,634 (75.4) <0.001
Cardiogenic shock at presentation 17 (6.9) 811 (4.5) 0.09
ST-segment elevation MI 70 (28.5) 3,846 (21.3) 0.008
Acute coronary syndrome 134 (54.5) 8,611 (47.6) 0.03
Left ventricular ejection fraction 48.9  13.6 52.8  13.2 <0.001
Values are n, mean  SD, or n (%).
MI ¼ myocardial infarction.









145 (49.7) 12,195 (42.9)
Left circumﬂex coronary artery 53 (18.2) 6,421 (22.6)
Right coronary artery 70 (24.0) 7,941 (27.9)
Left main trunk 8 (2.7) 1,187 (4.2)
Saphenous vein graft 16 (5.5) 696 (2.4)
Complex lesion (B2/C) 250 (85.6) 22,312 (78.4) 0.002
Chronic total occlusion 12 (4.1) 1,358 (4.8) 0.48
In-stent restenosis 44 (4.6) 909 (3.2) <0.001
Stent type <0.001
Bare-metal stent 118 (40.4) 10,590 (37.2)
Drug-eluting stent 174 (59.6) 17,857 (62.8)
First-generation
drug-eluting stent
92 (31.5) 5,780 (20.3)
Second-generation
drug-eluting stent
82 (28.1) 12,077 (42.5)
Total stented length, mm 27.3  15.2 24.8  15.2 0.001
QCA parameters
Lesion length, mm 16.2  10.9 15.2  9.1 0.06
Vessel size, mm 2.81  0.55 2.88  0.57 0.03
Minimum lumen diameter, mm
Before procedure 0.83  0.56 0.92  0.56 0.03
Post procedure 2.52  0.60 2.70  0.55 <0.001
Stenosis, %
Before procedure 69.8  19.6 68.1  17.9 0.22
Post procedure 13.1  13.5 10.0  9.3 <0.001
Maximal balloon diameter, mm 3.12  0.59 3.21  0.57 0.007
Balloon-to-vessel ratio 1.12  0.11 1.12  0.12 0.88
Maximal balloon pressure, mm 14.1  3.13 14.5  3.10 0.01
Values are n (%) or mean  SD. *p value was calculated with generalized estimating equation
models to adjust clustering data.
QCA ¼ quantitative coronary angiography.
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1270angiographic and procedural characteristics were also
signiﬁcantly different (Table 2). In short, greater cardiac
comorbidity, acute presentations and complex comorbidities
as well as higher lesion complexity were more likely to be
present in the stent thrombosis group.
At 3 years, deﬁnite stent thrombosis was found in 118
lesions (1.5%) in BMS, 92 lesions (2.2%) in G1-DES, and
82 lesions (1.0%) in G2-DES (Fig. 2). Only 4 patients with
stent thrombosis had different stent types in the same vessel
tract where the stent thrombosis was located.
On multivariate analysis adjusted for covariates, compared
with BMS, the adjusted odds ratio for deﬁnite stent
thrombosis was 2.05 (95% CI: 1.47 to 2.86; p < 0.001) in
G1-DES and 0.82 (95% CI: 0.56 to 1.19; p ¼ 0.30) in
G2-DES. Figure 3 shows the complete set of variables
included in the multivariate analysis. Diabetes mellitus,
current smoker, history of prior myocardial infarction,
clinical presentation with STEMI, complex lesion mor-
phology, in-stent restenosis, and a 5% increase in residual
stenosis were independent predictive factors for stent
thrombosis.
Incidence of deﬁnite stent thrombosis at 30 days. At 30
days, deﬁnite stent thrombosis occurred in 72 lesions (0.7%)
in BMS, in 44 lesions (0.7%) in G1-DES, and in 57 lesions
(0.5%) in G2-DES. After adjustment for intrapatient
correlation and differences in baseline characteristics, there
were no signiﬁcant differences among 3 stent generations
(adjusted rates of stent thrombosis: 0.6% in BMS, 0.7% in
G1-DES, and 0.5% in G2-DES, p ¼ 0.074).
Deﬁnite stent thrombosis between 1 and 3 years. Landmark
analysis was conducted for assessing the risk of very late
deﬁnite stent thrombosis across the groups between 1 and3 years. The rate of deﬁnite very late stent thrombosis was
0.5/1,000 patient-years in BMS, 3.3/1,000 patient-years
in G1-DES, and 0.4/1,000 patient-years in G2-DES
(Fig. 4). On multivariate analysis, the risk of very late stent
thrombosis was signiﬁcantly increased with G1-DES
compared with BMS (adjusted OR: 4.72; 95% CI: 2.01 to
11.1; p < 0.001). In contrast, the risk of very late stent
thrombosis was similar between G2-DES and BMS
(adjusted OR: 1.01; 95% CI: 0.32 to 3.25; p ¼ 0.98). Stent
implantation for in-stent restenosis and saphenous vein
grafts were independently associated with increased risk of
very late stent thrombosis (Fig. 5).Discussion
In the present study, we compared the relative risk of stent
thrombosis among 3 different intracoronary stent
Figure 2. Kaplan-Meier Curves of Stent Thrombosis Through 3 Years
Stent thrombosis in the 3 stent groups and risk estimates using the
bare-metal stent group as control. BMS ¼ bare-metal stents; G1-DES ¼ ﬁrst-
generation drug-eluting stents; G2-DES ¼ second-generation drug-eluting
stents, OR ¼ odds ratio.
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1271generations in 18,334 patients undergoing percutaneous
intervention at 2 centers in Munich, Germany, over a period
of 13 years. The main ﬁndings are: 1) percutaneous coronaryFigure 3. Risk Estimates of Predictors of Stent Thrombosis Through 3 Years
Plots of the OR for variables associated with a higher or lower risk of stent thrombosis
line the 95% conﬁdence interval. CI ¼ conﬁdence interval; EF ¼ ejection fraction, Ointervention with G1-DES compared with BMS had
a signiﬁcantly greater risk of deﬁnite stent thrombosis at
3 years; 2) intervention with G2-DES compared with BMS
was associated with a statistically similar risk of stent
thrombosis through 3 years; 3) the presence of diabetes
mellitus, current cigarette smoking, history of myocardial
infarction, STEMI at presentation, complex lesion mor-
phology, in-stent restenosis, and increased residual stenosis
after stenting independently predicted overall 3-year stent
thrombosis; and 4) beyond 1 year, the use of G1-DES but not
G2-DES predicted the risk of stent thrombosis.
Because concerns regarding the long-term safety of DES
such as late and very late stent thrombosis are thought to be
more apparent when DES were implanted for so-called off-
label use (22), the large patient cohort with unrestricted use
of intracoronary stents in our study strengthens the gener-
alizability of the results to real-world practice of percuta-
neous coronary interventions. The current study conﬁrms
the excess risk of stent thrombosis observed with G1-DES
compared with BMS. Moreover, there is strong evidence to
suggest that this risk has been eliminated with the use of
G2-DES. These ﬁndings are in line with observations from
recent studies reporting the improved safety of G2-DES
compared with G1-DES (14–18). Indeed, our data showed
a numerically lower incidence of stent thrombosis with G2-
DES compared with BMS, especially in the early phase of
follow-up. Although this difference was not statistically
signiﬁcant, it is consistent with observations by Palmerini
et al. (15) from an indirect comparison network. The center indicates the point estimate and the left and the right sides of the
R ¼ odds ratio; STEMI ¼ ST-segment elevation myocardial infarction.
Figure 4. Landmark Analysis of Stent Thrombosis
Stent thrombosis is shown for the ﬁrst year and for the period after the ﬁrst
year, separately. Abbreviations as in Figure 2.
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1272meta-analysis suggesting a lower risk of stent thrombosis in
patients with everolimus-eluting stents compared with both
noneverolimus DES and BMS. Patients enrolled in the
present study reﬂect everyday practice with minimal exclu-
sion criteria.Figure 5. Risk Estimates of Predictors of Very Late Stent Thrombosis
Plot of OR for variables associated with higher or lower risk of stent thrombosis. The
the 95% conﬁdence interval. Abbreviations as in Figure 3.The reason for the lower risk of stent thrombosis observed
with G2-DES remain unclear. Pathophysiological mecha-
nisms underlying improved safety with G2-DES compared
with their predecessors remain speculative, although newer
stent technologies such as more biocompatible and/or biode-
gradable polymers, improved drug-eluting kinetics, thinner
strut platforms, and their combination may contribute to
long-term lower thrombogenicity after implantation (23–27).
Indeed, pathological and intracoronary imaging studies
showed evidence of improved arterial healing including higher
neointimal coverage and fewer intrastent thrombi after G2-
DES implantation compared with G1-DES (28,29).
An additional consequence of delayed arterial healing after
coronary stenting is accelerated in-stent neoatherosclerosis.
Rupture of these plaques inside the implanted stent may
be another important trigger for late and very late stent
thrombosis (30). The more rapid time course of neo-
atherosclerotic change with G1-DES compared with BMS
(31–33) may explain the increased risk of very late stent
thrombosis with G1-DES. A post-mortem histological
study reported that the earliest atherosclerotic change began
at 4 months after sirolimus-eluting stent implantation,
whereas the same change in BMS lesions ﬁrst occurred
beyond 2 years (32).
Regarding potential mechanisms to explain the low inci-
dence of stent thrombosis events in the early phase of follow-
up after G2-DES implantation where re-endothelialization
of stent struts is expected to be incomplete (34), biocom-
patible polymer coatings such as ﬂuoropolymer in thecenter indicates the point estimate and the left and the right ends of the line
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1273everolimus-eluting stent (23,27), BioLinx polymer in the
Resolute zotarolimus-eluting stent (35), and polylactic acid
biodegradable polymers (16,26) may act protectively against
thrombogenicity of the foreign bodies in the implanted
segment.
Consistent with previous studies (36,37), we found that
patient comorbidities and lesion complexity were associated
with the overall incidence of deﬁnite stent thrombosis at
3 years. In addition, it is noteworthy that restenting for in-
stent restenosis was the strongest predictive factor for both
overall and very late stent thrombosis. Using DES for in-
stent restenosis has been supported by evidence reporting its
superior efﬁcacy in preventing recurrence of restenosis
compared with both plain balloon angioplasty (38,39) and
vascular brachytherapy (40,41). However, these studies were
not designed and powered to evaluate long-term safety of
this treatment strategy. Emerging technologies using time-
limited systems for drug delivery to the diseased vessel such
as drug-eluting balloon or drug-eluting biodegradable scaf-
folds may be a promising alternative (42–44).
After a series of studies reporting increased death or
myocardial infarction after DES implantation in mid-2006
(45–47), increasing concern for late stent thrombosis resul-
ted in an abrupt decline in the use of DES (48). The present
study supports the improved long-term safety of the inter-
ventions with the G2-DES over its predecessors and, at the
same time, suggests that timely and accurate reporting of
outcomes after the introduction of new technologies allows
better understanding of potential problems and facilitates
evolution of these devices.
Study limitations. First, this study lacks a randomized
design, and stent selection was based only on the period-
speciﬁc availability of the devices. As such, ﬁndings in
relation to the comparative safety of different stent genera-
tions should be interpreted with caution and are hypothesis
generating in nature. However, analyses were adjusted for
confounders using multivariate analysis with generalized
estimation equation models, thus minimizing the potential
for bias. Second, we did not include duration of or
compliance with medications in this study because it is
difﬁcult to reliably ascertain data concerning the prevalence
of medication adherence or the timing of antiplatelet therapy
discontinuation in such a large-scale registry. Third, this
study included only cases adjudicated as Academic Research
Consortium–deﬁnite stent thrombosis (i.e., conﬁrmed by
angiography or autopsy). Although this may have resulted in
an underestimation of the true prevalence of stent throm-
bosis, each individual event could be clearly attributed to
a single stent analyzed at the lesion level. Moreover, although
use of a lesion-level analysis is important to permit capture
of lesion-speciﬁc factors relevant to stent thrombosis, to
minimize potential bias introduced by intrapatient correla-
tion, an inherent issue in lesion-speciﬁc analysis, comparisons
across the groups were adjusted using generalized estimationequation models. Fourth, the ability of multivariate analysis
to fully adjust for the considerable differences in baseline
characteristics as well as the improvement in interventional
and periprocedural treatment strategies over time might be
questionable. More frequent post-dilation, thrombus aspi-
ration, and the use of new antithrombotic medications may
have contributed to an improved outcome among patients
with G2-DES compared with patients with BMS and
G1-DES. Finally, grouping of stents as BMS, G1-DES, and
G2-DES is necessarily arbitrary and cannot fully capture
differences across different BMS or DES platforms.Conclusions
In a large cohort of unselected patients undergoing coronary
stenting compared with BMS, there was a signiﬁcantly
increased risk of stent thrombosis at 3 years with G1-DES
driven by an excess of stent thrombosis beyond 1 year.
G2-DES were associated with similar risk of stent throm-
bosis compared with BMS.
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